Should You Buy AbbVie Inc (ABBV) Stock on Friday?

AbbVie Inc (ABBV) stock is higher by 1.36% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

AbbVie Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ABBV!

See Full ABBV Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ABBV Stock Today?

AbbVie Inc (ABBV) stock is up 1.1% while the S&P 500 is lower by -1.77% as of 3:01 PM on Friday, Dec 3. ABBV has risen $1.29 from the previous closing price of $116.81 on volume of 3,491,407 shares. Over the past year the S&P 500 is higher by 22.54% while ABBV has risen 12.49%. ABBV earned $4.20 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 28.12. To screen for more stocks like AbbVie Inc click here.

More About AbbVie Inc

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health. Click Here to get the full Stock Report for AbbVie Inc stock.